Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386979775> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4386979775 abstract "Abstract Background and objectives Pediatric B‐cell non‐Hodgkin lymphomas (NHL) in low‐ and middle‐income countries (LMICs) have historically had inferior outcomes due to higher treatment‐related mortality (TRM) and relapses. To address this issue, we evaluated the impact of reducing chemotherapy dose intensity by 25% and adding rituximab on outcomes in pediatric B‐NHL. Patients and methods Patients, less than 18 years of age with group B and C disease as per the Lymphome Malin de Burkitt (LMB) risk stratification were enrolled between September 2017 and October 2022. The LMB‐89 protocol, with a 25% reduction in all chemotherapy doses and the addition of rituximab, was administered. The response was assessed using positron emission tomography with computed tomography (PET/CT) after four cycles of chemotherapy (interim) and at the end of treatment. Results The study included 25 patients with a median age of 6.9 years, among whom 20 (80%) were males. Twenty patients had group B and five had group C disease. Complete metabolic response (CMR) was achieved by 22/25 (88%) patients, and three (12%) achieved partial metabolic response (PMR) in the interim PET/CT. At the end of treatment, 22/24 (92%) patients achieved CMR, one had PMR, and one had progressive disease. The median follow‐up was 45 months (range: 3–71 months). The 4‐year event‐free survival and overall survival were 88% and 92%, respectively. There were two deaths, one due to disease progression and the other due to sepsis. Conclusion Our study demonstrates a significant improvement in outcomes in pediatric B‐NHL compared to previous reports from LMICs, achieved through a 25% reduction in chemotherapy dose intensity and the addition of rituximab." @default.
- W4386979775 created "2023-09-24" @default.
- W4386979775 creator A5023012523 @default.
- W4386979775 creator A5039441410 @default.
- W4386979775 creator A5047199872 @default.
- W4386979775 creator A5052438565 @default.
- W4386979775 creator A5067888908 @default.
- W4386979775 creator A5083516218 @default.
- W4386979775 date "2023-09-23" @default.
- W4386979775 modified "2023-10-04" @default.
- W4386979775 title "Reducing chemotherapy dose intensity by 25% and adding rituximab improves survival in pediatric mature B‐cell non‐Hodgkin lymphoma in LMIC setting" @default.
- W4386979775 cites W1867200418 @default.
- W4386979775 cites W2045940197 @default.
- W4386979775 cites W2156073127 @default.
- W4386979775 cites W2162244898 @default.
- W4386979775 cites W2337911387 @default.
- W4386979775 cites W2555475526 @default.
- W4386979775 cites W2602116487 @default.
- W4386979775 cites W2606364858 @default.
- W4386979775 cites W2742101984 @default.
- W4386979775 cites W2791370983 @default.
- W4386979775 cites W2791433690 @default.
- W4386979775 cites W2806838331 @default.
- W4386979775 cites W2912859263 @default.
- W4386979775 cites W2970600574 @default.
- W4386979775 cites W3031891765 @default.
- W4386979775 cites W3081868842 @default.
- W4386979775 cites W4200142166 @default.
- W4386979775 cites W4220703073 @default.
- W4386979775 doi "https://doi.org/10.1002/pbc.30694" @default.
- W4386979775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37740580" @default.
- W4386979775 hasPublicationYear "2023" @default.
- W4386979775 type Work @default.
- W4386979775 citedByCount "0" @default.
- W4386979775 crossrefType "journal-article" @default.
- W4386979775 hasAuthorship W4386979775A5023012523 @default.
- W4386979775 hasAuthorship W4386979775A5039441410 @default.
- W4386979775 hasAuthorship W4386979775A5047199872 @default.
- W4386979775 hasAuthorship W4386979775A5052438565 @default.
- W4386979775 hasAuthorship W4386979775A5067888908 @default.
- W4386979775 hasAuthorship W4386979775A5083516218 @default.
- W4386979775 hasConcept C126322002 @default.
- W4386979775 hasConcept C141071460 @default.
- W4386979775 hasConcept C143998085 @default.
- W4386979775 hasConcept C2776694085 @default.
- W4386979775 hasConcept C2778822529 @default.
- W4386979775 hasConcept C2779338263 @default.
- W4386979775 hasConcept C2780653079 @default.
- W4386979775 hasConcept C71924100 @default.
- W4386979775 hasConceptScore W4386979775C126322002 @default.
- W4386979775 hasConceptScore W4386979775C141071460 @default.
- W4386979775 hasConceptScore W4386979775C143998085 @default.
- W4386979775 hasConceptScore W4386979775C2776694085 @default.
- W4386979775 hasConceptScore W4386979775C2778822529 @default.
- W4386979775 hasConceptScore W4386979775C2779338263 @default.
- W4386979775 hasConceptScore W4386979775C2780653079 @default.
- W4386979775 hasConceptScore W4386979775C71924100 @default.
- W4386979775 hasLocation W43869797751 @default.
- W4386979775 hasLocation W43869797752 @default.
- W4386979775 hasOpenAccess W4386979775 @default.
- W4386979775 hasPrimaryLocation W43869797751 @default.
- W4386979775 hasRelatedWork W2003938723 @default.
- W4386979775 hasRelatedWork W2047967234 @default.
- W4386979775 hasRelatedWork W2118496982 @default.
- W4386979775 hasRelatedWork W2143803333 @default.
- W4386979775 hasRelatedWork W2294919913 @default.
- W4386979775 hasRelatedWork W2374533761 @default.
- W4386979775 hasRelatedWork W2418204902 @default.
- W4386979775 hasRelatedWork W2439875401 @default.
- W4386979775 hasRelatedWork W2569260518 @default.
- W4386979775 hasRelatedWork W2525756941 @default.
- W4386979775 isParatext "false" @default.
- W4386979775 isRetracted "false" @default.
- W4386979775 workType "article" @default.